Anti-inflammatory effects of SGLT2 inhibitors in atherosclerosis, non-alcoholic fatty liver disease, chronic inflammatory bowel disease, Alzheimer’s disease, viral infections, and other diseases were also reported [11,16,35,36]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.